Stifel analyst Jonathan Block lowered the firm's price target on Beta Bionics to $20 from $22 and keeps a Buy rating on the shares. Q1 results were "relatively solid," with modest revenue upside despite a higher-than-expected percent of new patients starts occurring through Pharmacy lowering the upfront revenue recognition, the analyst tells investors.
